Nippon Chemiphar Co., Ltd.

Depression Drugs Manufacturers to Capitalize on High Demand for Tricyclic Antidepressants with Minimal Side Effects The most recent study from Fact.MR on the market for depression drugs offers a 10-year prediction through 2021 and beyond. The study explains important factors, including drivers, constraints, and opportunities. The report was divided into various segments such as drug type, drug class, disease type, distribution channel, and region to provide the information in an engaging manner. NEW YORK, Aug. 11, 2022 /PRNewswire/ -- The global depression drugs market was estimated to be worth US$ 13 Billion in 2020. By 2031, sales of depression drugs are expected to surpass US$ 20 Billion and are projected to grow at a CAGR of 4% in the forecast period (2021-2031). Over the assessment period of 2021 to 2031, demand for serotonin-norepinephrine reuptake inhibitors (SNRIs), which currently holds the largest market share, is anticipated to rise at a CAGR of 2%. The World Health Organization (WHO) claims that depression, which affects more than 350 million people globally, is one of the main causes of disability. The WHO further mentions that more women are affected by depression than men and about 5% of adults suffer from depression across the globe. For Critical Insights on this Market, Request for More Info at: On account of this, key players are focusing on developing novel techniques for the production of tricyclic antidepressants with minimal side effects and long-term outcomes. They are also adopting new ingredients for producing unique medications for treating depression. Key Takeaways: The global depression drugs market stood at US$ 13 Billion in 2020 and held about 50% share of the psychotropic drugs industry. The North America depression drugs market is likely to grow 1.3x by 2031. The U.S. depression drugs market is anticipated to surge 1.5x by the end of 2031 with rising geriatric population. By drug class, the serotonin-norepinephrine reuptake inhibitors (SNRIs) category is likely to increase 2x over the evaluation period. Top 5 companies operating in the global depression drugs market are estimated to hold about 40% of share through 2021 and beyond. Growth Drivers: Rising incidence of chronic illnesses, including anxiety, depression, and other conditions related to mental health is likely to drive growth. Increased sales of selective serotonin reuptake inhibitors (SSRIs) and high demand for tricyclic antidepressants are expected to boost growth. Restraints: Antidepressants can have various side effects, including decreased libido, stomach upset, and fatigue, which may hinder their sales. Individuals often feel ambivalence about taking medicines and thus skip doses or do not disclose their use of antidepressants to providers, which can hamper growth. To Gain In-Depth Insights on Depression Drugs Market, Request Methodology at Competitive Landscape: Leading producers of depression medications are adopting sustainable growth strategies to broaden their product offerings, maintain their leading positions in international markets, develop their client bases, and gain more market share. For instance, In June 2021, a combined R&D agreement and an agreement for clinical research of the new antidepressant candidate called NC-2800 were announced by Nippon Chemiphar Co., Ltd and Sumitomo Dainippon Pharma Co., Ltd. Key Companies Profiled by Fact. MR Johnson and Johnson Sebela Pharmaceutical Inc. Takeda Pharmaceutical Company GlaxoSmithKline Novartis AG Allergan USA Inc. AstraZeneca Pfizer Inc Eli Lilly and Company Otsuka Pharmaceutical Co. Ltd. Alkermes Plc Bristol Myers Squibb Co. H. Lundbeck Teva Pharmaceutical Industries Ltd. More Valuable Insights on Depression Drugs Market In the latest study, Fact.MR offers a detailed study on global depression drugs market for the forecast period of 2021 to 2031. This study also highlights key drivers promoting the sales of depression drugs through detailed segmentation as follows: By Drug Type: Generic Depression Drugs Branded Depression Drugs By Drug Class: Serotonin-norepinephrine Reuptake Inhibitors (SNRIs) Selective Serotonin Reuptake Inhibitors (SSRIs) Atypical Antipsychotics Central Nervous System (CNS) Stimulants Tricyclic Antidepressants Monoamine Oxidase Inhibitors By Disease Type: Major Depressive Disorder Obsessive-Compulsive Disorder Generalized Anxiety Disorder Panic Disorder Schizophrenia Bipolar 1 Disorder By Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies By Region: North America Latin America Europe East Asia South Asia Oceania Middle East Africa Interested to Procure The Data? Inquire here Key Questions Covered in the Depression Drugs Market Report What is the projected value of the depression drugs market in 2021? At what rate will the global depression drugs market grow until 2031? Which are the factors hampering the growth in the depression drugs market? Which region is expected to lead in the depression drugs market during 2021-2031? Which are the factors driving the depression drugs market during the forecast period? What is the expected market value of the depression drugs market during the forecast period? Explore Fact.MR's Coverage on the Healthcare Domain Drug Delivery System Market: The market for drug delivery systems was valued at around US$ 40 Billion in 2022. It is anticipated to grow at a CAGR of more than 7.8% from 2022 to 2032 and reach about US$ 80 Billion by 2032. Innovative drug delivery systems are being developed to address solubility problems and increase the lipid solubility of pharmaceuticals. Drug Eluting Balloon Catheter Market: Over the next 10 years, it is predicted that the global market for drug-eluting balloon catheters would grow at a healthy CAGR of 18%. Sales of polyurethane drug-eluting balloon catheters are anticipated to exhibit high growth in the next decade. Drug Discovery Services Market: The market for drug discovery services is anticipated to grow from US$ 19 Billion in 2022 to US$ 50 Billion by 2032. It is likely to exhibit a CAGR of 10.1% from 2022 to 2032. In the upcoming decade, drug discovery services are projected to exhibit high demand due to surging outsourcing of these services to CROs. Novel Drug Delivery Systems (NDDS) Market: Rising healthcare expenditure, supportive government initiatives, and the presence of key drug delivery system providers are the prime factors that are expected to drive NDDS market growth in this region through 2027. Drug Discovery Technologies Market: Worldwide demand for drug discovery technologies is anticipated to surge at a CAGR of 8.4% from 2022 to 2026. The AI drug discovery industry is expected to provide lucrative opportunities for new drug discovery technology providers. Check it Out More Reports by Fact.MR on Healthcare Industry About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. We understand that making sense of the vast labyrinth of data can be overwhelming for businesses. That's why focus on offering insights that can actually make a difference to bottom-lines. Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership. Explore All the Industries Reports Here Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583 E: [email protected] Follow Us: LinkedIn | Twitter | Blog Logo: SOURCE Fact.MR

Los Angeles, USA, Aug. 31, 2021 (GLOBE NEWSWIRE) -- DelveInsight Estimates a Promising Gout Pipeline Owing to an Expected Entry of Novel Therapeutic Agents Around 40+ key companies are developing therapies for Gout. Selecta Biosciences appears to have the upper leg being the only company with its Gout drug candidate in the most advanced stage (Phase III). DelveInsight’s ‘Gout Pipeline Insights’ report offers comprehensive coverage of the emerging Gout therapeutics landscape in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive, and abandoned drugs agents. The Gout Pipeline report provides a holistic picture of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Gout domain. Some of the key highlights from the Gout Pipeline report: Request for Sample to know more about the therapies that are set to grab maximum patient pool @ Gout Emerging Therapies and Forecast Gout is a chronic disease that is caused due to excess accumulation of uric acid in the body, a condition referred to as hyperuricemia. It is a painful and crystal-induced form of arthritis in which crystals of monosodium urate (MSU) precipitate and deposit in joints of lower limbs. Gout is treatable with medications and changes in diet and lifestyle. For more information on emerging drugs, visit Gout Pipeline Analysis Gout Pipeline Drugs Request for Sample to know more @ Gout Pipeline Analysis, Key Companies, and Futuristic Trends Gout Therapeutic Assessment The Gout Pipeline report lays down complete insights into active Gout pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action. By Product Type By Stage By Molecule Type By Route of Administration By Mechanism of Action By Targets Get in touch with our Business executive for Informative Business Decisions, Licensing Services  and Consulting Solutions Scope of the Report Coverage: GlobalKey Players: Protalix BioTherapeutics, Shanton Pharma, Horizon Therapeutics, JW Pharmaceutical, Jiangsu Hengrui Medicine Co., Nippon Chemiphar, Sinovent, LG Chem, Selecta Biosciences, TWi Biotechnology, Olatec Therapeutics, Hinova pharmaceuticals, Dyve Biosciences, InventisBio, Arrowhead Pharmaceuticals, Wellstat Therapeutics Corporation, Acquist Therapeutics, TaiwanJ Pharmaceuticals, Atom Bioscience Key Gout Pipeline Therapies: PRX-115, SAP-001, HZN-003, URC-102, SHR4640, NC-2700, XNW3009, LC350189, SEL-212, AC-201, Dapansutrile, HP501, DYV700, D-0120, ARO-XDH, WT-2107, ACQT1127, TJC0434, ABP-072, and many others. Reach out @ Gout Pipeline: Novel therapies and Emerging technologies Table of Contents Visit to know more of what’s covered @ Gout Emerging Therapies, Treatments and Ongoing Clinical Trials Related ReportsAcute Gout Flare MarketDelveInsight's "Acute gout Flare - Market Insights, Epidemiology, and Market Forecast-2030" report. Chronic Refractory Gout MarketDelveInsight's "Chronic Refractory Gout - Market Insights, Epidemiology, and Market Forecast-2030" report. Gout MarketDelveInsight's "Gout - Market Insights, Epidemiology, and Market Forecast-2030" report. Hyperkalemia Japan MarketDelveInsight’s ‘Hyperkalemia —Market Insights, Epidemiology, and Market Forecast–2030’ report. Acute Pancreatitis Market SizeDelveInsight's "Acute Pancreatitis (AP) Market Insights, Epidemiology and Market Forecast-2028" report. Browse through blog postsAngelman syndrome PipelineAutoimmune Diseases Market and Key Pharma Players Involved About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News